These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8701411)

  • 21. Oral, more than transdermal, estrogen therapy improves lipids and lipoprotein(a) in postmenopausal women: a randomized, placebo-controlled study.
    Hemelaar M; van der Mooren MJ; Mijatovic V; Bouman AA; Schijf CP; Kroeks MV; Franke HR; Kenemans P
    Menopause; 2003; 10(6):550-8. PubMed ID: 14627865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term results of transdermal estrogen replacement therapy in cardiovascular disease-free postmenopausal females with and without hypertension.
    Modena MG; Rossi R; Muia N; Origliani G; Rombolà O; Molinari R
    G Ital Cardiol; 1998 Jun; 28(6):636-44. PubMed ID: 9672776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestin on quality of life in postmenopausal women.
    Hilditch JR; Lewis J; Ross AH; Peter A; van Maris B; Franssen E; Charles J; Norton P; Dunn EV
    Maturitas; 1996 Jul; 24(3):177-84. PubMed ID: 8844631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of transdermal estrogen replacement therapy on hyperandrogenicity and glucose homeostasis in postmenopausal women with NIDDM.
    Andersson B; Mattsson LA
    Acta Obstet Gynecol Scand; 1999 Mar; 78(3):260-1. PubMed ID: 10078591
    [No Abstract]   [Full Text] [Related]  

  • 26. Vasomotor hot flashes and heart rate variability: a placebo-controlled trial of postmenopausal hormone therapy.
    Lantto H; Haapalahti P; Tuomikoski P; Viitasalo M; Väänänen H; Sovijärvi AR; Ylikorkala O; Mikkola TS
    Menopause; 2012 Jan; 19(1):82-8. PubMed ID: 21934534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT.
    Serrano D; Mariani L; Mora S; Guerrieri-Gonzaga A; Cazzaniga M; Daldoss C; Ramazzotto F; Feroce I; Decensi A; Bonanni B
    Maturitas; 2006 Aug; 55(1):69-75. PubMed ID: 16500052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A double-blind, randomized, comparative study evaluating clinical effects of two sequential estradiol-progestogen combinations containing either desogestrel or medroxyprogesterone acetate in climacteric women.
    Saure A; Planellas J; Poulsen HK; Jaszczak P
    Maturitas; 2000 Feb; 34(2):133-42. PubMed ID: 10714908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
    Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Activity of plasminogen activator inhibitor (PAI-1) in plasma of women treated after menopause with hormone replacement therapy].
    Ciepłuch R; Czestochowska E
    Pol Tyg Lek; 1995 Sep; 50(36-39):13-5. PubMed ID: 8650021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of postmenopausal estrogen/progestin replacement therapy on LDL particles; comparison of transdermal and oral treatment regimens.
    Lahdenperä S; Puolakka J; Pyörälä T; Luotola H; Taskinen MR
    Atherosclerosis; 1996 May; 122(2):153-62. PubMed ID: 8769679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized placebo-controlled study of the effect of transdermal vs. oral estradiol with or without gestodene on homocysteine levels.
    Smolders RG; van der Mooren MJ; Teerlink T; Merkus JM; Kroeks MV; Franke HR; Stehouwer CD; Kenemans P
    Fertil Steril; 2003 Feb; 79(2):261-7. PubMed ID: 12568832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, double-blind, placebo-controlled, cross-over trial to assess the side effects of medroxyprogesterone acetate in hormone replacement therapy.
    Kirkham C; Hahn PM; Van Vugt DA; Carmichael JA; Reid RL
    Obstet Gynecol; 1991 Jul; 78(1):93-7. PubMed ID: 1828550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of transdermal oestradiol and oral progestogens on haemostasis variables.
    Kroon UB; Tengborn L; Rita H; Bäckström AC
    Br J Obstet Gynaecol; 1997 Nov; 104 Suppl 16():32-7. PubMed ID: 9389781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transdermal estradiol and medroxyprogesterone acetate in hormone replacement therapy are both antioxidants.
    Tranquilli AL; Mazzanti L; Cugini AM; Cester N; Garzetti GG; Romanini C
    Gynecol Endocrinol; 1995 Jun; 9(2):137-41. PubMed ID: 7502690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.
    Scarabin PY; Alhenc-Gelas M; Plu-Bureau G; Taisne P; Agher R; Aiach M
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3071-8. PubMed ID: 9409295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of hormone therapy for treating dry eye syndrome in postmenopausal women: a randomized trial.
    Piwkumsribonruang N; Somboonporn W; Luanratanakorn P; Kaewrudee S; Tharnprisan P; Soontrapa S
    J Med Assoc Thai; 2010 Jun; 93(6):647-52. PubMed ID: 20572368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women.
    Boschetti C; Cortellaro M; Nencioni T; Bertolli V; Della Volpe A; Zanussi C
    Thromb Res; 1991 Apr; 62(1-2):1-8. PubMed ID: 1649497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cardiovascular risk factors.
    Chen FP; Lee N; Soong YK; Huang KE
    Menopause; 2001; 8(5):347-52. PubMed ID: 11528361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.